To eliminate cranial irradiation (CrRT)-related sequelae and to minimize the adverse impact of traumatic lumbar puncture (TLP) with blasts, the Taiwan Pediatric Oncology Group (TPOG) introduced a modified central nervous system (CNS)-directed regimen characterized by delayed triple intrathecal therapy (TIT) and the omission of CrRT for all children with newly diagnosed acute lymphoblastic leukemia (ALL). METHODS: This study compared the treatment outcomes of patients overall and patients with a non-CNS-1 status (CNS-2, CNS-3, or TLP with blasts) in 2 treatment eras, one before and another after the revision of the TPOG-ALL-2002 protocol by the introduction of the modification (era 1 [2002][2003][2004][2005][2006][2007][2008] with CrRT and era 2 [2009][2010][2011][2012] with delayed first TIT and no CrRT). RESULTS: There were no statistically significant differences in major outcomes between the 903 patients treated in era 1 and the 444 patients treated in era 2: the 5-year event-free survival (EFS) rates were 75.7% ± 1.4% and 72.1% ± 2.4%, respectively (P = .260), and the cumulative risks of isolated CNS relapse were 4.0% ± 0.7% and 4.1% ± 1.0%, respectively (P = .960). There were also no differences between non-CNS-1 patients treated in era 1 (n = 76) and era 2 (n =28): the 5-year EFS rates were 52.3% ± 5.8% and 62.9% ± 9.4%, respectively (P = .199), and the cumulative risks of isolated CNS relapse were 6.3% ± 3.1% and 3.6% ± 3.5%, respectively (P = .639). Notably, TLP with blasts was completely eliminated after the first TIT was delayed in era 2. CONCLUSIONS: The delay of the first TIT until the clearance of circulating blasts and the total omission of CrRT did not compromise survival or CNS control in patients with childhood ALL, including those with a non-CNS-1 status. Cancer 2018;124:4538-4547.
INTRODUCTION
Cranial irradiation (CrRT), once a standard central nervous system (CNS)-directed therapy for childhood acute lymphoblastic leukemia (ALL), has increasingly been omitted from protocols because of its many recognized complications, including second cancers (especially brain tumors), a decreased intelligence quotient, cognitive deficits, and
Cancer December 1, 2018 endocrinopathy. [1] [2] [3] [4] The most recent protocols for ALL limit the use of prophylactic CrRT to 0% to 33% of childhood ALL patients. 5, 6 To abolish CrRT-related sequelae and minimize the adverse prognostic impact of traumatic lumbar puncture (TLP) with blasts, beginning in 1999, we conducted a single-institution study at Mackay Memorial Hospital to modify CNS-directed therapy with delayed triple intrathecal therapy (TIT) upon the clearance of circulating blasts or up to 10 days after multidrug induction and with the omission of CrRT for all risk groups with newly diagnosed ALL. 7 We reasoned that the delayed intrathecal therapy approach would reduce the proportion of patients having TLP with blasts, an adverse risk feature associated with poor event-free survival (EFS) and an increased risk of CNS relapse. 8 Among the 152 patients treated in the Mackay study, the estimated 5-year EFS and overall survival (OS) rates (presented as mean ± standard error) were 84.2% ± 3.0% and 90.6% ± 2.4%, respectively. There were no isolated CNS relapses, and only 2 patients had combined CNS relapses. The 7-year cumulative risk of any CNS relapse was 1.4% ± 1.0%. Hence, the Mackay study improved CNS control and survival without compromising the systemic control of leukemia, and it enhanced the quality of life of patients by omitting the use of prophylactic CrRT. 7 These results led us to revise the protocol of a multi-institutional study (Taiwan Pediatric Oncology Group Acute Lymphoblastic Leukemia 2002 [TPOG- ALL-2002] ) to add this modified CNS treatment in January 2009. A comparison of overall treatment outcomes between patients treated in the early era with prophylactic CrRT and patients treated in the recent era with delayed intrathecal therapy and the omission of prophylactic CrRT has been previously reported. 9 We now provide additional analysis with longer follow-up and show that the modified CNS treatment also did not compromise the outcomes of patients with a non-CNS-1 status in this groupwide study.
MATERIALS AND METHODS

Patients
From 2002 to 2012, all children in Taiwan with newly diagnosed ALL (0-18 years old) were enrolled in the TPOG-ALL-2002 study. Those with B-precursor ALL were stratified into standard-risk (SR), high-risk (HR), and very high-risk (VHR) groups according to their age, leukocyte count, cytogenetics, and molecular analysis at diagnosis. Patients with T-cell ALL were considered part of the VHR group. Details of the risk stratification and treatment regimens were previously published 7, 9, 10 (see the supporting information). All protocols were approved by the institutional review boards of the participating institutions. Written informed consent was obtained from the patients, parents, or guardians.
CNS-Directed Therapy
The CNS status was defined as follows: CNS-1, no blasts in a nontraumatic sample; CNS-2, fewer than 5 leukocytes per microliter with blasts in a nontraumatic sample; CNS-3, 5 or more leukocytes per microliter with blasts in a nontraumatic sample or the presence of cranial nerve palsy; and TLP, 10 or more erythrocytes per microliter with or without blasts.
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Since January 2009, diagnostic lumbar puncture and the first TIT injection were not performed until blasts were no longer detectable in peripheral blood, but they were performed no later than 10 days after the initiation of induction therapy. Exceptions were made for patients who presented with cranial nerve palsy or other evidence of CNS disease; in these cases, lumbar puncture and the first TIT dose were administered on the day of diagnosis. SR patients with cranial nerve palsy, detectable blasts in peripheral blood on day 8, or a CNS-3 status were classified as HR.
SR patients with CNS-1 received 14 doses of TIT, whereas those with CNS-2 or TLP with blasts received 2 additional TIT doses during induction therapy and another 3 during maintenance therapy for a total of 19 doses. In the HR group, those with CNS-1 were given 17 doses of TIT; this escalated to 25 doses for those with CNS-2, CNS-3, or TLP with blasts, including 2 doses during induction and 6 during maintenance therapy.
Before 2009, 18 Gy of CrRT was introduced prophylactically to VHR patients with a CNS-1 status at the beginning of maintenance therapy, and this was coupled with 5 concomitant TIT treatments; those younger than 2 years were excluded and were given TIT instead. VHR patients with CNS-2, CNS-3, or TLP with blasts at diagnosis received TIT weekly during induction until cerebrospinal fluid (CSF) remission was achieved and then once every 4 weeks during maintenance therapy before 24 Gy of CrRT. Among SR and HR patients, only those with refractory CNS leukemia at diagnosis (i.e., a failure to clear CSF blasts after 3 consecutive TIT treatments) received 24 Gy of CrRT with 5 concomitant TIT treatments at 1 year of remission. Since 2009, all patients have been treated with TIT alone without CrRT, and the doses and schedule of TIT have remained the same. The doses and timing of CNS-directed therapy by risk
Cancer December 1, 2018 group, CNS status, and treatment era are summarized in Table 1 .
In this trial, the correction of thrombocytopenia before intrathecal treatment, deep sedation during the procedure, and the practitioners most skilled at performing lumbar puncture were recommended.
Statistical Analysis
Differences between categorical variables were examined with Fisher's exact test or the chi-square test. The Kaplan-Meier method was used to estimate survival rates, with differences compared with the log-rank test. The duration of OS was defined as the time from diagnosis to the date of death. The duration of EFS was defined as the time from diagnosis to the date of failure (relapse, death, or the development of a second malignancy) or the last follow-up date for all patients who lacked an adverse event. Patients who did not achieve complete remission were considered to have an EFS of zero. Logistic regression analysis was used to estimate relative risk in the multivariate analysis.
For patients who achieved complete remission, cumulative incidence functions of isolated CNS or any CNS relapse were estimated with the method of Kalbfleisch and Prentice. 12 An isolated CNS relapse was defined as one without simultaneous relapse at another site, and any CNS relapse was defined as CNS relapse accompanied or not by relapse in the bone marrow or any other extramedullary site. All reported P values were based on 2-sided tests, and they were considered statistically significant if they were less than .05. Data were analyzed with IBM SPSS software (release 21.0; IBM, Armonk, New York).
RESULTS
Altogether, 1366 patients were enrolled in the TPOG-ALL-2002 study. 9 Twelve patients in 2002-2008 (era 1) and 7 patients in 2009-2012 (era 2) were excluded because of an unknown CNS status. Thus, 903 patients in era 1 and 444 patients treated with delayed TIT and without CrRT in era 2 were included in this study for further analysis. The presenting features of the patients in the 2 eras were balanced. 9 In this study, the prevalence of patients with hyperdiploidy was relatively high and that of t(12;21) positivity was quite low among the patients tested (63% of the total patients; Table 2 ). There were no significant differences between the 2 eras in the rates of EFS (75.7% ± 1.4% vs 72.1% ± 2.4%; P = .260) Cancer December 1, 2018 or OS (83.0% ± 1.3% vs 79.4% ± 2.1%; P = .069) or in the cumulative incidences of any CNS (6.3% ± 0.8% vs 5.4% ± 1.2%; P = .563) or isolated CNS relapse (4.0% ± 0.7% vs 4.1% ± 1.0%; P = .960; Fig. 1 ). There were also no significant differences in the cumulative incidence of relapse, isolated bone marrow relapse, or non-CNS relapse between patients treated in the 2 treatment eras (Fig. 2) .
Clinical and Biological Features of Patients With a Non-CNS-1 Status
A total of 76 patients were classified as having a non-CNS-1 status (i.e., CNS-2, CNS-3, or TLP with blasts) in era 1, and there were 28 in era 2. Their clinical and biological characteristics are summarized in Table 2 . The clinical and biological characteristics did not differ significantly between non-CNS-1 patients in the 2 treatment eras, and this suggests that delayed TIT did not select out higher risk patients with a non-CNS-1 status. Among patients with non-CNS-1 leukemia treated in era 1, the median age at diagnosis was 4. leukocyte count (>100 × 10 9 /L), an HR/VHR classification, and an MLL rearrangement showed a significant association with a non-CNS-1 status; however, only an HR/VHR designation retained statistical significance in a multivariate analysis (odds ratio, 2.625; 95% confidence interval, 1.586-4.344; P < .001). In era 2, the median age at diagnosis was 6.0 years (IQR, 3.5-12.9 years), and 2 patients were infants. The median leukocyte count was 43.1 × 10 9 /L (IQR, 10.0-161.4 × 10 9 /L), with 9 patients having counts greater than 100 × 10 9 /L. There were 22 patients with B-precursor ALL, and there were 6 patients with T-cell ALL. As in era 1, the risk classification of HR/VHR was the only significant predictor of a non-CNS-1 status in the multivariate model (odds ratio, 2.861; 95% confidence interval, 1.261-6.489; P = .012).
Treatment Outcomes for Non-CNS-1 Patients Treated in Different Eras
The numbers of patients with CNS-2, CNS-3, and TLP with blasts were 35, 25, and 16, respectively, in era 1 and 19, 9, and 0, respectively, in era 2. Although there was no difference in the frequency of patients with CNS-2 or CNS-3 between the 2 eras (60 of 903 patients vs 28 of 444 patients; P = .810), the classification of TLP with blasts was completely eliminated after the first TIT treatment was delayed in era 2. The 5-year EFS and OS rates among non-CNS-1 patients treated in era 1 were 52.3% ± 5.8% and 61.8% ± 5.7%, respectively. The cumulative risk estimates for any CNS or isolated CNS relapse were 17.3% ± 4.8% and 6.3% ± 3.1% at 5 years, respectively. The 5-year EFS for this group after modified treatment in era 2 was 62.9% ± 9.4%, whereas the OS was 77.9% ± 8.0%; the cumulative risk estimates for any CNS relapse and isolated CNS relapse were both 3.6% ± 3.5%. Importantly, these comparisons between treatment eras (Table 3 and Fig. 3 ) did not show any statistically significant differences that would indicate a loss of efficacy due to the delay in the first TIT treatment and the omission of CrRT altogether. Instead, the cumulative rates of CNS relapse were uniformly lower in era 2 than era 1 (Table 3) , and the only relapse after treatment modification occurred 8 months after remission.
DISCUSSION
In this study, we show that modified CNS-directed therapy with delayed administration of the first TIT treatment and total omission of CrRT did not compromise the outcomes of treatment for childhood ALL, even when the analyses were limited to patients with a non-CNS-1 status. Our results are in line with previous studies showing that CrRT can be successfully omitted for all risk groups of childhood ALL in the context of effective systemic chemotherapy and intrathecal therapy. 13, 14 It should be noted that our results were obtained with a relatively high number of TIT treatments (14-19 doses in 6 analyzed the impact of CrRT on clinical outcomes among patients treated in 10 major collaborative studies of childhood ALL with substantial differences in the proportions of patients receiving CrRT, which ranged from 0% to 33%. Their meta-analysis identified patients with CNS-3 at diagnosis as the only subgroup with a reduction in the rate of any or isolated CNS relapses after CrRT, but there were no significant differences in the cumulative risk of any adverse events or in survival between patients with a CNS-3 status treated with or without CrRT. They concluded that the use of prophylactic CrRT did not have an important impact on the risk of treatment outcomes in almost all subgroups of ALL treated with contemporary protocols.
The reported rates of CNS-2 and CNS-3 leukemia in children have ranged from 5.4% to 32.2% and from 1.6% to 4.7%, respectively, 5, 6 with EFS and OS rates for patients with CNS disease ranging from 43% to 86% and from 64% to 95%, respectively, depending on whether infants or patients with a CNS-2 status or TLP with blasts were enrolled. 5, 6, 8, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In the TPOG-ALL-2002 study, the incidence rates for CNS-2 and CNS-3 involvement were similar to those cited previously and did not change significantly from one treatment era to the next. Treatment outcomes in patients with a CNS-2 or CNS-3 status were also comparable to results obtained in contemporary trials that adopted the same definition of CNS status. 8, [14] [15] [16] [17] 24, 28 In fact, in our study, non-CNS-1 patients in era 2 tended to have better EFS and OS than those in era 1 (Fig. 3A) , and this suggests that the delay in TIT actually could improve outcomes. In addition, the advances in supportive care, especially with the prophylactic use of antibiotics and antifungals, 29 the decrease in dropout rates, and the wide coverage of National Health Insurance in Taiwan also might have contributed to the trend of outcome improvements in era 2. Notably, the EFS of patients with a non-CNS-1 status was inferior to that of CNS-1 patients only in era 1 (P < .001) and not in era 2 (P = .115).
TLP with blasts has been reported to occur in 5.6% to 14.5% of patients with childhood ALL if the first puncture is performed at the time of diagnosis. 5, 14, 30 TLP contaminated with blasts has also been shown to be a risk factor for CNS relapse. 8 Several studies have reported EFS rates ranging from 56% to 81%. 5, 8, [14] [15] [16] [17] 28, 31 Importantly, in our study, the modification of delaying the first TIT treatment eliminated the occurrence of TLP with blasts altogether. The other advantages of delaying the initial intrathecal therapy include the avoidance of sedation of patients with a mediastinal mass at diagnosis and the elimination of the potential toxicities of delayed clearance of methotrexate in patients with acute kidney injury because they are not exposed to methotrexate, which is a major component of intrathecal therapy.
The outcomes of CNS involvement in ALL patients with a non-CNS-1 status are not routinely reported. Cancer December 1, 2018
Pui and Howard 5 reviewed this issue and showed that the risk of any CNS relapse at 5 years ranges from 2.3% to 20.2% for CNS-2, from 10% to 33.3% for CNS-3, and from 8.0% to 9.1% for TLP with blasts. In a recent Children's Oncology Group study of patients with SR and HR B-cell ALL, the 5-year any CNS relapse rate was 5.6% for patients with a CNS-2 status and 5.1% for those with a CNS-3 status who received 18 Gy of CrRT; this was significantly higher than the 2.0% for patients with a CNS-1 status. 27 In the current study, the 5-year cumulative risk for any CNS relapse in non-CNS-1 patients decreased from 17.3% in era 1 to 3.6% in era 2.
Furthermore, the Mackay study in Taiwan  7 continued to enroll a total of 187 newly diagnosed patients between 1999 and 2012. All the lumbar puncture and TIT procedures were performed by the most skillful practitioners in our division. In this cohort, only a single infant had a CNS-2 status, and none had CNS-3 involvement or TLP with blasts. As of December 31, 2015, there were only 4 patients with any type of CNS relapse and 1 patient with an isolated CNS relapse. The 5-year EFS and OS rates and cumulative rates of any and isolated CNS relapse were 84.5% ± 2.7%, 91.8% ± 2.0%, 2.3% ± 2.1%, and 0.6% ± 0.6%, respectively (Fig. 4) . No SR patients 
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Cancer December 1, 2018 needed to be upgraded to HR because of a CNS-3 status or TLP with blasts. The advances in supportive care, especially the use of prophylactic antibiotics and antifungals, 29 and better compliance with the treatment protocol have additional positive impacts on the improvement of the treatment outcomes in this single-institution study. Altogether, these findings were pivotal in shaping the design of the nationwide TPOG-ALL-2002 study because they suggested the feasibility of a favorable outcome with a delayed first TIT injection, less intensive systemic chemotherapy, and uniform omission of CrRT, which could be expected to benefit patients.
In conclusion, a delay of the first TIT procedure until the clearance of circulating blasts together with the complete omission of CrRT did not compromise either the survival or the control of CNS leukemia for children with ALL, including those with a non-CNS-1 status. In the longer term, the omission of CrRT for all patients should lead to much lower rates of second cancers and cognitive deficits. 
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